Daniel Haders II, Ph.D.

Daniel Haders II, Ph.D. has extensive experience in the fields of healthcare, technology, and entrepreneurship. Daniel is the Co-Founder, CEO, and Board Director of Model Medicines, a pharmatech company that utilizes artificial intelligence and machine learning for drug discovery and development. Daniel also holds the position of Managing Director in Digital Health at Nex Cubed, where they support and accelerates frontier tech companies. Additionally, Dr. Haders has served as an Operating Partner at Sway Ventures, an advisor at MedCrypt, and a Senior Strategic Advisor at QuiO. Daniel has been involved in various leadership and advisory roles at other organizations such as AppliedVR, University of California San Diego, Columbia Technology Ventures, Together.Health, and University of California, San Francisco. Dr. Haders' expertise lies in digital health, healthcare administration, business development, and entrepreneurship.

Daniel Haders II, Ph.D. began their education at Columbia University in 1997, where they studied Biomedical Engineering and Materials Science and Engineering. Daniel completed their Bachelor of Science (BS) degree at Columbia in 2001.

After a few years, in 2002, Daniel pursued further education at Rutgers University, where they focused on Biomedical Engineering and Materials Science and Engineering. Daniel successfully completed their Ph.D. at Rutgers in 2008.

During their time as a Ph.D. student, in 2005, Daniel had the opportunity to visit the University of Oxford as a Recognized Visiting Graduate Student. Daniel engaged in study and research in the field of Materials Science and Engineering during their visit.

In 2009, Daniel briefly attended Harvard Business School to enhance their knowledge in Leadership and Strategy in Pharmaceuticals and Biotech. Although the precise degree name is not provided for their Harvard Business School education, it is implied that they attended a program or course related to their field of interest.

Based on the chronological information provided, Daniel Haders II, Ph.D. holds a Bachelor of Science (BS) degree from Columbia University, a Ph.D. in Biomedical Engineering and Materials Science and Engineering from Rutgers University, and has also pursued additional education in the field of Leadership and Strategy in Pharmaceuticals and Biotech at Harvard Business School.